Clinical Comparative Study Of Chemotherapy Combined With DC-CIK Cells Biotherapy In Treatment Of Patients With Colorectal Cancer

Objectives Chemotherapy and biological DC-CIK cell therapy comparing colorectal cancer. A retrospective analysis of the hospital past the diagnosis and treatment of 80 cases of chemotherapy combined with DC-CIK cell biological therapy and chemotherapy alone in patients with colorectal cancer were collected clinical data, therapeutic efficacy and safety of contrast differences observed between the two. Analysis of prognostic factors for colorectal cancer was observed chemotherapy chemotherapy DC-CIK cell biological therapy for colorectal cancer patients improve immune function, reduce symptoms and prolong survival whether clinical advantage.Methods Clinical data in our hospital from January 2008 to January 2014 during chemotherapy combined with CIK cells for treating 40 cases of colorectal cancer patients collate, according to the patient’s sex, age, TNM clinical stage, tumor differentiation,metastasis, surgical, adjuvant radiotherapy as an indicator 1:1 pairing method selected in our hospital while receiving chemotherapy treatment of 40 patients as a control group of conventional chemotherapy FOLFOX regimen, undergraduate according to NCCN guidelines for patients with individualized case of feed chemotherapy. Biological treatment options for DC + CIK cell biological therapy.Results 1 General information: the two groups in terms of sex, age, tumor size, tumor location, degree of differentiation, histological type, clinical stage, metastasis, surgical and adjuvant radiotherapy etc., there is no significance difference(P>0.05).2 Before and after treatment compared to the situation in general: the two groups before treatment, after two cycles of peripheral blood T cell subsets show differences in the study group and the control group were CD3 + T cell content(66.3 ± 15.6),respectively, after two cycles of treatment,(56.3 ± 13.3), two groups of patients cells CD3 + CD8 + T content was(39.7 ± 8.3),(28.5 ± 7.0), two groups of patients cells CD3+ CD4 + T content, respectively(31.6 ± 10.2),(36.9 ± 9.5), NK cell content was(6.1 ±1.9),(3.8 ± 2.8), the cell contents of NKT was(8.8 ± 4.5),(4.6 ± 2.1), the cell contents of regulatory T cells(Treg) was(6.1±1.9)、(3.8±2.8). the indicators were statistically significant(P<0.05). CD3 + T cells, CD3 + CD8 + T cells, NK cells, NKT cells was significantly increased after treatment study group patients, CD3 + CD4 + T cells, and regulatory T cells(Treg) decreased change significant difference. these indicators have changed before treatment, but not statistically significant.3 Before and after treatment CD4 + T cells in the main cytokine levels: the two groups of patients after two cycles of CD4 + T cells in IFN-γ content was(30.8 ± 3.2)and(18.2 ± 1.9), IL-2 contents were(13.2 ± 2.8) and(8.7 ± 2.3), IL-6 contents were(4.2± 1.2) and(13.2 ± 0.8),(P<0.05).4 Comparison of the two groups of Ⅲ-Ⅳ adverse reactions: Ⅲ-IV toxicities study group and the control group, the former leukopenia, anemia, thrombocytopenia, nausea,vomiting, liver dysfunction were lower than the control group, the overall incidence of5.0%, also lower than the 15.0% in the control group,(P<0.05).5 Two groups of patients before and after treatment quality of life scores: study group of patients treated after the quality of life score was significantly increased(P<0.0l). Quality of life in patients in the control group decreased significantly, the quality of life scores before and after treatment, there was statistical difference(P<0.01).6 Group of patients in 1 year, 2 years, 3-year survival rates were 100.0%, 92.8%,72.0% was significantly higher than 97.8%, 83.6%, 53.6%, Group of patients in 1 year, 2years, 3-year disease-free survival rates were 93.5%, 65.3%, 56.3% was significantly higher than 68.8%, 42.6%, 40.5%,(P<0.05).Conclusions It found that DC-CIK cells to kill tumor cells with high activity and high proliferation rate, broad tumoricidal range, low cytotoxicity and other special advantages,thus gradually applied to the treatment of cancer. Cancer patients because of immune cells have long been suppressed, against the action of their own lack of cancer cells, the consequences of cancer cells to proliferate indefinitely. By taking the biological treatment of patients with immune cells extracted and cultured in vitro amplification, induction,antitumor activity and so the number of immune cells increased significantly, then returned to the patient in vivo activation and proliferation, inhibition played the role of tumor recurrence and metastasis, while protecting its own healthy cells from damage and improve the quality of life of patients.